Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain.

ABSTRACT: With less than 50% of patients responding to the current standard of care and poor efficacy and selectivity of current treatments, neuropathic pain continues to be an area of considerable unmet medical need. Biological therapeutics such as monoclonal antibodies (mAbs) provide better intrinsic selectivity; however, delivery to the central nervous system (CNS) remains a challenge. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is well described in inflammation-induced pain, and early-phase clinical trials evaluating its antagonism have exemplified its importance as a peripheral pain target. Here, we investigate the role of this cytokine in a murine model of traumatic nerve injury and show that deletion of the GM-CSF receptor or treatment with an antagonizing mAb alleviates pain. W

SUBMITTER: Nicol LSC 

PROVIDER: S-EPMC5828377 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature